KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Shares Outstanding (2016 - 2025)

CRISPR Therapeutics AG's Shares Outstanding history spans 11 years, with the latest figure at $8.0 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 1900.0% year-over-year to $8.0 million; the TTM value through Dec 2025 reached $8.0 million, up 1900.0%, while the annual FY2025 figure was $8.0 million, 1900.0% up from the prior year.
  • Shares Outstanding for Q4 2025 was $8.0 million at CRISPR Therapeutics AG, up from $7.0 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $88.4 million in Q2 2025 and bottomed at $170316.0 in Q1 2024.
  • The 5-year median for Shares Outstanding is $7.5 million (2025), against an average of $37.8 million.
  • The largest annual shift saw Shares Outstanding crashed 99.76% in 2021 before it surged 46949.41% in 2024.
  • A 5-year view of Shares Outstanding shows it stood at $180316.0 in 2021, then skyrocketed by 43441.59% to $78.5 million in 2022, then plummeted by 99.36% to $500000.0 in 2023, then decreased by 20.0% to $400000.0 in 2024, then soared by 1900.0% to $8.0 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Shares Outstanding are $8.0 million (Q4 2025), $7.0 million (Q3 2025), and $88.4 million (Q2 2025).